Swiss drug maker Roche has filed a lawsuit against Pfizer in a Wilmington, Delaware federal court, seeking to block the rival developer from launching a biosimilar trastuzumab in the United States.
Swiss drug maker Roche has filed a lawsuit against Pfizer in a Wilmington, Delaware federal court, seeking to block the rival developer from launching a biosimilar trastuzumab in the United States.
Bloomberg Technology reports that Roche subsidiary Genentech, maker of the blockbuster Herceptin, claims that a biosimilar would infringe on 40 of its patents. Genentech’s complaint asks the court to order compensation for lost sales if Pfizer launches a biosimilar prior to Herceptin’s US patent expiry.
While this legal action marks the first time Roche has sued over a biosimilar in a United States court, the lawsuit is not the first legal challenge related to Pfizer’s development of its proposed trastuzumab molecule. In July 2017, the US Patent Trial and Appeal Board (PTAB) instituted Pfizer’s petitions for inter partes reviews (IPRs) filed by Pfizer subsidiary Hospira against 3 patents covering Herceptin (though the PTAB denied an IPR petition for a fourth patent). Then, in October 2017, Pfizer filed another petition for an IPR of an additional Herceptin patent.
Legal action over trastuzumab is also not Pfizer’s first foray into legal battles over biosimilars; Pfizer launched the first biosimilar infliximab product (Inflectra) in the United States in October 2016, and has proactively litigated against Johnson & Johnson, sponsor of the reference infliximab (Remicade), claiming that Johnson & Johnson engaged in anti-competitive practices that were intended to block Inflectra from gaining formulary placement.
While Pfizer has not yet announced its submission of a Biologics License Application for its proposed trastuzumab biosimilar, it has released positive data from a comparative clinical trial comparing PF-05280014 to reference trastuzumab in patients with operable HER2-positive early breast cancer. The study demonstrated that PF-05280014 had similar safety, efficacy, and immunogenicity to its reference, and that it was non-inferior, in terms of pharmacokinetics, to the reference drug.
Pfizer’s pipeline also contains a number of other proposed biosimilars; the drug maker reports that it is in phase 3 development of biosimilars referencing adalimumab (Humira), bevacizumab (Avastin), epoetin alfa (Epogen, Procrit), and rituximab (Rituxan, MabThera). Forbes reports that the total sales of the reference products targeted by Pfizer totaled over $35 billion in 2014, and that “Theoretically speaking, replacing [these drugs’] entire sales with biosimilars even with a 50% pricing discount will open up a market worth nearly $18 billion for Pfizer.”
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.